Institution
University of Brescia
Education•Brescia, Italy•
About: University of Brescia is a education organization based out in Brescia, Italy. It is known for research contribution in the topics: Population & Heart failure. The organization has 8090 authors who have published 24576 publications receiving 780862 citations. The organization is also known as: Università degli Studi di Brescia & Universita degli Studi di Brescia.
Topics: Population, Heart failure, Medicine, Cancer, Blood pressure
Papers published on a yearly basis
Papers
More filters
••
Katholieke Universiteit Leuven1, Rikshospitalet–Radiumhospitalet2, University of British Columbia3, Royal United Hospital4, VU University Amsterdam5, Erasmus University Rotterdam6, University of Oviedo7, Sapienza University of Rome8, Leiden University9, Complutense University of Madrid10, European Organisation for Research and Treatment of Cancer11, University of Brescia12, Gartnavel General Hospital13
TL;DR: Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulked surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study.
Abstract: Of the 670 patients randomly assigned to a study treatment, 632 (94.3%) were eligible and started the treatment. The majority of these patients had extensive stage IIIC or IV disease at primary debulking surgery (metastatic lesions that were larger than 5 cm in diameter in 74.5% of patients and larger than 10 cm in 61.6%). The largest residual tumor was 1 cm or less in diameter in 41.6% of patients after primary debulking and in 80.6% of patients after interval debulking. Postoperative rates of adverse effects and mortality tended to be higher after primary debulking than after interval debulking. The hazard ratio for death (intention-to-treat analysis) in the group assigned to neoadjuvant chemotherapy followed by interval debulking, as compared with the group assigned to primary debulking surgery followed by chemotherapy, was 0.98 (90% confidence interval [CI], 0.84 to 1.13; P = 0.01 for noninferiority), and the hazard ratio for progressive disease was 1.01 (90% CI, 0.89 to 1.15). Complete resection of all macroscopic disease (at primary or interval surgery) was the strongest independent variable in predicting overall survival. Conclusions Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulking surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study. Complete resection of all macroscopic disease, whether performed as primary treatment or after neoadjuvant chemotherapy, remains the objective whenever cytoreductive surgery is performed. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00003636.)
1,865 citations
••
The Catholic University of America1, Royal Prince Alfred Hospital2, University of Toronto3, Centre for Addiction and Mental Health4, Università Campus Bio-Medico5, University of Eastern Finland6, Monash University7, Medical University of South Carolina8, Paris 12 Val de Marne University9, University of Regensburg10, University of Brescia11, University of Göttingen12, Beth Israel Deaconess Medical Center13, University of Siena14, University College London15, Copenhagen University Hospital16, Fukushima Medical University17, University of Tübingen18
TL;DR: These guidelines provide an up-date of previous IFCN report on “Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application” and include some recent extensions and developments.
1,850 citations
••
TL;DR: Results, with the distinct cell phenotype, indicate that plasmacytoid monocytes represent a specialized cell lineage that enters inflamed lymph nodes at high endothelial venules, where it produces type I interferon.
Abstract: We have identified two cell subsets in human blood based on the lack of lineage markers (lin-) and the differential expression of immunoglobulin-like transcript receptor 1 (ILT1) and ILT3. One subset (lin-/ILT3+/ILT1+) is related to myeloid dendritic cells. The other subset (lin-/ILT3+/ILT1+) corresponds to 'plasmacytoid monocytes'. These cells are found in inflamed lymph nodes in and around the high endothelial venules. They express CD62L and CXCR3, and produce extremely large amounts of type I interferon after stimulation with influenza virus or CD40L. These results, with the distinct cell phenotype, indicate that plasmacytoid monocytes represent a specialized cell lineage that enters inflamed lymph nodes at high endothelial venules, where it produces type I interferon. Plasmacytoid monocytes may protect other cells from viral infections and promote survival of antigen-activated T cells.
1,791 citations
••
TL;DR: This paper extends a discontinuous finite element discretization originally considered for hyperbolic systems such as the Euler equations to the case of the Navier?Stokes equations by treating the viscous terms with a mixed formulation, and finds the method is ideally suited to compute high-order accurate solution of theNavier?
1,750 citations
••
TL;DR: The results suggest that carvedilol extends survival compared with metoprolol.
1,718 citations
Authors
Showing all 8188 results
Name | H-index | Papers | Citations |
---|---|---|---|
Alberto Mantovani | 183 | 1397 | 163826 |
Marco Colonna | 139 | 512 | 71166 |
Roberto Ferrari | 133 | 1654 | 103824 |
Lorenzo Moretta | 131 | 658 | 63417 |
Ole Røhne | 128 | 1038 | 75752 |
Yehuda Shoenfeld | 125 | 1629 | 77195 |
Andrea Carlo Marini | 123 | 1236 | 72959 |
Alessandro Moretta | 123 | 415 | 50509 |
Leonardo M. Fabbri | 109 | 566 | 60838 |
Philip A. Poole-Wilson | 105 | 443 | 66861 |
Hans D. Ochs | 102 | 419 | 39881 |
Giovanni B. Frisoni | 101 | 871 | 46199 |
Marco Metra | 99 | 825 | 49886 |
Joel D. Kopple | 99 | 388 | 34317 |
Silvano Sozzani | 98 | 335 | 43598 |